RNS Reach Story
Go to market news section View chart   Print
Company Clinigen Group plc
TIDM CLIN
Headline

Organizational Changes to Scale up for Growth

Released 07:00 09-Jul-2013
Number 8587I07

RNS Number : 8587I
Clinigen Group plc
09 July 2013
 

 

 

Clinigen Group Makes Organizational Changes to Scale-up
for Future Business Growth

Burton-on-Trent, UK - 9 July 2013 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN) today announced that it has made organizational changes to prepare and support the Group to scale-up in line with its five year growth strategy and support recent organic growth and the integration of two new products in the Specialty Pharmaceuticals business.

Under the new structure, Shaun Chilton, formerly the Chief Operating Officer in charge of the Clinigen CTS (Clinical Trial Supply) and Clinigen GAP operational businesses, has been appointed Chief Operating Officer for the Group and will add management of the Specialty Pharmaceutical business to his responsibilities. He will be supported in this role by the appointment of new Senior Vice Presidents to run each of these three operating businesses.

Clinigen GAP (Global Access Programs) will be led by Mark Corbett, formerly Vice President of GAP. Lorann Morse will become Senior Vice President of Clinigen CTS (Clinical Trial Supply) having joined Clinigen from Myoderm where she was Director of Client Services. She will be based in Philadelphia and brings valuable regional expertise and insight to the CTS business.  David Bryant will move from his role as Business Development Director to head up Clinigen SP (Specialty Pharmaceuticals). Anton Jenkins, previously COO of Clinigen SP, has been appointed to Business Development Director,  performing a key role that is focused on the further in-licensing and acquisition of new products.

Peter George, Chief Executive Officer, Clinigen Group said, "Over the past three years, we have seen significant organic growth of CTS and GAP and the expansion of our product portfolio with the acquisition of Cardioxane from Novartis and in-licensing of VIBATIV from Theravance. Now is a logical time for us to ensure we have the right infrastructure and people in place to be able to scale-up further for future growth and achieve our ambitious plans. I am extremely happy with these appointments; we have high quality people running our operational businesses with a wealth of sector experience."

- Ends -

About Clinigen Group

Clinigen is a specialty global pharmaceutical products business headquartered in the UK, with offices in the US and Japan. The Group has three operating business; Clinigen SP (Specialty Pharmaceuticals), Clinigen CTS (Clinical Trials Supply), and Clinigen GAP (Global Access Programs). The SP business focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. Clinigen CTS sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies.  Clinigen GAP specializes in the consultancy, development, management and implementation of global access programs for biotechnology and pharmaceutical companies. For more information, please visit www.clinigengroup.com.

 

 

Contact Details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Peter George, Group Chief Executive Officer


Shaun Chilton, Chief Operating Officer




College Hill (media relations)

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell/Stefanie Bacher/Jen Lewis

Email: clinigen@collegehill.com



 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASSFESAFDSELW
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Organizational Changes to Scale up for Growth - RNS